Vaxess Technologies, a Cambridge, Massachusetts life sciences company developing a shelf-stable, sustained-release vaccine patch, has announced that Fenel Eloi has joined its board of directors.
Fenel Eloi brings to Vaxess more than 30 years experience as a leader in the life sciences industry. He is currently managing partner of P&M capital partners, a private angel investment firm. Previously, Eloi was the Chief Financial Officer and then Chief Operating Officer of Cell Signaling Technology, a privately held life sciences company, where he oversaw significant growth of the business over a period of 12 years and provided leadership in the transformation of the company to a global operation.
Prior to that, Eloi was the Chief Operating Officer and Chief Financial Officer of Interleukin Genetics, Inc., a formerly NASDAQ-listed diagnostic company. Additional positions included Chief Financial Officer at LifeCell Corp and Genome Therapeutics Corp, both formerly NASDAQ-listed companies.
In addition to his board role with Vaxess, Eloi currently serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company; Ultivue, Inc., a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing; 908 Devices, Inc., a publicly-traded mass spectrometry device company; and VIC, a technology venture development company for high impact life science ventures. Eloi previously served on the board of Cell Signaling Technology, Inc., a reagents company, and BioHelix Corporation, a diagnostics company.